Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

iRETINA

Financiado

Development of a multilayered and bioprinted iPSC-derived retinal model with use...

Development of a multilayered and bioprinted iPSC-derived retinal model with use in preclinical and toxicological testing Age-related macular degeneration (AMD) encompass the most prevalent cause of vision-loss in elderly people in developed countries. One of the main hurdles restraining the development of efficient treatments against AMD is the inab... ver más

28/02/2026

FUNDACION PUBLICA...

207K€

Presupuesto del proyecto: 207K€

Líder del proyecto

FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 14M€

Ver 3 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-06-30

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021 ExpectedOutcome:

I+D

Cerrada hace 3 años

0% 100% 100%

3 Participantes

FUNDACION PUBLICA ANDALUZA P...

206.64K€ | Lider

DCS

N.D. | Participante

BICO GROUP

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-124033OB-I00 PLURIPOTENCIA ADQUIRIDA: ANALISIS DE LA REPROGRAMACION CELUL... 109K€ Cerrado

SAF2015-72617-EXP REPROGRAMACION Y REGENERACION TISULAR A PARTIR DE MICROVESIC... 48K€ Cerrado

BFU2012-35258 DESARROLLO DE CELULAS PLURIPOTENTES INDUCIDAS (IPS) HUMANAS... 138K€ Cerrado

EIN2019-103021 MODELADO DE UNA RETINA ARTIFICIAL MEDIANTE CELULAS Y TEJIDOS... 12K€ Cerrado

PDC2022-133261-C22 DEMOSTRACION DE LA EFICACIA DE LA REGENERACION TISULAR EN UN... 50K€ Cerrado

BES-2011-043382 BASES DE ENFERMEDADES CUTANEAS: DESARROLLO DE MODELOS EXPERI... 43K€ Cerrado

Duración del proyecto: 43 meses Fecha Inicio: 2022-06-30
Fecha Fin: 2026-02-28

Líder del proyecto

FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 14M€

Presupuesto del proyecto 207K€

Descripción del proyecto Age-related macular degeneration (AMD) encompass the most prevalent cause of vision-loss in elderly people in developed countries. One of the main hurdles restraining the development of efficient treatments against AMD is the inability of current animal, 2D-cellular and organoid-based models to completely recapitulate the pathophysiology of this disease. The goal of the iRETINA project is to bioprint an in-vitro human retinal model using isolated endothelial and retinal cells derived from iPSCs. The result will be a functional and vascularized iPSC-derived tissue resembling the native stratified retina that could serve as a preclinical and toxicological model for drug development and for the study of complex phenomena such as allogenic immune response. In order to achieve this goal, the iRETINA project will focus at three different levels: 1) implementing state-of-the-art genome editing tools for the development of retinal cell differentiation and enrichment strategies from healthy and AMD-patient iPSC; 2) developing new methodologies for bioprinting endothelial and retinal cells aiming to preserve cell viability, synaptic connectivity and structural integrity; 3) proof of concept testing to evaluate the usefulness of the artificial retina as a bona fide in vitro retinal model. The nature of this project is strongly multidisciplinary and involves the collaboration of basic researchers with experts in the fields of ophthalmology, immunology and biomaterial sciences. The results of this proposal have the potential to represent a true technological and scientific breakthrough that will result in better organ and disease modeling, and reduced laboratory animal use, eventually minimizing the burden and complexity of preclinical trials required for the development of novel pharmacological and cell replacement therapies against AMD.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores